Clinical Trial Update: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ACT-334441 in systemic lupus erythematosus has completed with results posted, evaluating safety, tolerability, pharmacokinetics, and biolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• ACT-334441

Snippet

Sponsor: Viatris Innovation GmbH | Conditions: Systemic Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-26